Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Top Cited Papers
- 4 May 2002
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 359 (9317), 1541-1549
- https://doi.org/10.1016/s0140-6736(02)08512-4
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentThe New England Journal of Medicine, 2001
- Malignancy following remicadeTM therapy: Incidence and characteristicsGastroenterology, 2001
- Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complicationGastroenterology, 2000
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 1997
- Methotrexate for the Treatment of Crohn's DiseaseThe New England Journal of Medicine, 1995
- Frequency of glucocorticoid resistance and dependency in Crohn's disease.Gut, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Lymphoma in inflammatory bowel diseaseCancer, 1992
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989